← Eichor
Study identifier: NCT05900882 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Condition: Multiple Myeloma  ·  Sponsor: The First Affiliated Hospital with Nanjing Medical University

PhasePhase 2
Planned participants35
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.

This description comes directly from the study's public registry record.

Talk to the study team

Yuanyuan Jin, Doctor  ·  025-83714511  ·  827508088@qq.com

Lijuan Chen, Doctor  ·  025-83714511  ·  chenljb@126.com

Always discuss trial participation with your own doctor first.

Locations (6)

Changzhou Second People's HospitalChangzhou, Jiangsu, ChinaNot Yet Recruiting
Nanjing First People's HospitalNanjing, Jiangsu, ChinaNot Yet Recruiting
The First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu, ChinaRecruiting
Affiliated Hospital of Nantong UniversityNantong, Jiangsu, ChinaNot Yet Recruiting
Taizhou People's HospitalTaizhou, Jiangsu, ChinaNot Yet Recruiting
Yancheng First People's HospitalYancheng, Jiangsu, ChinaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05900882